Filing Flows › Health Care › BioStem Technologies (BSEM)
BioStem Technologies (BSEM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · BioStem Technologies (BSEM) Q2 2026 earnings results →
Q2 2026 Revenue down 28% year over year to $7.9M · 114¢ of every $1 of revenue lost · operating margin -106.3%
BioStem Technologies made $7.9M in Q2 2026 (-28% Y/Y): Hospital $6.7M, Physician Office $1.1M, Other $89K. Operating margin -106.3%, net loss $9.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.9M in Q2 2026, down 28% year over year. Hospital was the largest line at 85% of revenue. Physician Office lost $9.9M year over year (down 90%), 322% of the total change.
Gross margin was 61.3%, down 32.5 points from a year earlier. Operating costs exceeded revenue by $8.4M, an operating margin of -106.3%. Operating expenses grew 30% against a revenue fall of 28%. The fastest-growing cost line was Other operating costs (+1035%). The quarter ended with a net loss of $9.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $7.9M | -28% | -106.3% | −$9.0M | — |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BioStem Technologies
(Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”).
In its own words, from its 8-K, filed Aug 12, 2026.
BioStem Technologies against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -28% against the peers' median +11%. Operating margin: -106.3% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BSEM BioStem Technologies | Q2 2026 | $7.9M | -28% | -106.3% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: BioStem Technologies 10-Q on SEC EDGAR · CIK 1658678 · Biological Products, (No Diagnostic Substances)
More on BSEM
History
Every quarter: Q2 2026 results